Circulating APP, NCAM and Aβ serve as biomarkers for Alzheimer's disease

Alzheimer's disease (AD) is the most common neurodegenerative disease and the early diagnosis and intervention are important for valid treatment of AD. However, there are few biomarkers for the diagnosis and monitoring of AD. In the present study, circulating APP, NCAM, Aβ40, and Aβ42 were measured in order to identify which marker or combination of markers could be useful, cost-effective and noninvasive biomarkers for diagnosing and continuously monitoring AD. The results showed that circulating APP, NCAM, Aβ40, and Aβ42 were different between the AD group and the control group. Importantly, the combination of the four biomarkers had the highest AUC (0.997) with the highest sensitivity (98.5). Therefore, circulating APP, NCAM, Aβ40, and Aβ42 can be used as desirable biomarkers for AD diagnosis and monitoring.